BCRX — Q2 2026 Financial Report Analysis

BioCryst's second quarter of 2026 looks spectacular on paper: total revenue up 34% to $218.3 million and net income of $78.4 million, against $5.1 million a year earlier. But a quarter of that revenue, $55.7 million, was a one-time licensing payment from European partner Neopharmed Gentili for the rights to sell navenibart, a drug that is still in late-stage trials. The recurring business is ORLADEYO, a once-daily pill that prevents attacks of hereditary angioedema (HAE, a rare genetic disease that causes sudden, sometimes life-threatening swelling). ORLADEYO brought in $158.2 million, only 1% more than a year ago as reported, because BioCryst sold its European ORLADEYO business in October 2025. On the US-and-partners business it still owns, ORLADEYO grew about 10%.

At a glance

• $158.2 million ORLADEYO revenue (+1% reported, +10% excluding Europe): the core drug is still growing at a double-digit pace once the sold European business is stripped out of last year's figure.
• $55.7 million of one-time license revenue: this is almost all of the $68.7 million jump in operating profit; without it, Q2 operating profit would have been roughly $43 million, not $98.5 million.
• Total revenue guidance raised to $690–715 million (from $635–660 million in May), while ORLADEYO guidance stayed at $625–645 million: the raise reflects the licensing deal, not faster drug sales.

The numbers

Operating margin is the share of revenue left after running the business (making the drug, research, sales and admin costs), before interest and tax. Non-GAAP figures are the company's own adjusted numbers, which here exclude stock-based pay and, for 2025, the European business that was sold.

What drove the quarter

ORLADEYO: price and volume in the US. The 10-Q attributes a $14.7 million increase in ORLADEYO revenue (excluding the sold European business) to "a net price increase and an increase in volume of direct sales." That was offset by $13.3 million of European revenue that no longer exists after the sale to Neopharmed on October 1, 2025. So the reported +1% hides a business that is still growing about 10% on a like-for-like basis.

The navenibart Europe license. In May BioCryst licensed European rights to navenibart (its long-acting injectable HAE drug, acquired with Astria Therapeutics in January 2026) to an Irish affiliate of Neopharmed. Neopharmed paid $70.0 million upfront, with up to $275.0 million more in milestones and royalties of 18% to 30% of European sales if it is approved. BioCryst booked $54.5 million of that immediately as license revenue plus $1.2 million for research services; the remaining $14.3 million sits on the balance sheet as deferred revenue (cash already received, to be recognised over the next few years as BioCryst does the related trial work).

Peramivir fell away. License and other revenue would have been higher still, but direct sales of peramivir (RAPIVAB, an injectable flu drug) to the US Department of Health and Human Services dropped by $6.2 million after the government's initial 12-month ordering period expired in September 2025 and no further ordering periods were exercised.

Costs moved in opposite directions. Selling, general and administrative expense fell 27% to $64.0 million, mostly because the European sales organisation is gone and last year's quarter carried $5.9 million of sale-related transaction costs. Research and development rose 20% to $52.0 million, which the company attributes mainly to the navenibart ALPHA-ORBIT pivotal trial it took on with Astria.

What the headline numbers hide

• The profit jump is mostly a one-off. The $55.7 million Neopharmed revenue has almost no direct cost attached in the quarter. Take it out and Q2 GAAP operating profit is about $43 million, or roughly 26% of the remaining $162.5 million of revenue: an improvement on last year's 18.2% margin, but nowhere near the 45.1% headline.
• The first half was a large loss. For the six months BioCryst reported a net loss of $643.4 million ($2.59 per share), driven by a non-cash $697.8 million "acquired in-process R&D" charge for navenibart when it bought Astria. Accounting rules expense the value of an unapproved drug immediately rather than carrying it as an asset, so the charge reflects what was paid, not money lost in operations.
• Cash is real, but modest relative to the debt. Operating cash flow for the first half was $42.6 million (versus $13.8 million a year earlier), helped by the upfront payment and a $10.8 million rise in deferred revenue. The company says it was cash-flow positive in Q2 even without the Neopharmed money. But it paid $489.5 million in cash for Astria, funded by a new $395.4 million Blackstone term loan, on top of a $426.8 million royalty financing obligation (money raised by selling a share of future ORLADEYO royalties). Stockholders' equity is negative $454.3 million.
• Interest is a big drag. Interest expense of $21.7 million in the quarter, much of it non-cash amortisation on the royalty financing, ate about a fifth of operating profit.
• More shares. Diluted shares rose 21% to 265.2 million (from 219.9 million), mainly from stock issued in the Astria deal. EPS growth came from higher operating profit, not buybacks or a lower tax rate (tax was $1.1 million in both years).
• Receivables are in line. Receivables were $110.8 million at June 30 versus $106.8 million at year-end, a 4% rise, consistent with sales growth.

Takeaway: Strip out the $55.7 million one-time navenibart license fee and BioCryst's quarter is a steady ~10% grower on its core drug with operating margins in the mid-20s, not a company earning 45% margins. The business can now fund itself, but it carries about $820 million of loan and royalty financing obligations, so ORLADEYO's growth has to keep paying for navenibart's trial.

Outlook

Management kept 2026 ORLADEYO revenue guidance at $625–645 million and raised total revenue guidance to $690–715 million (from $635–660 million on May 6), the difference being the navenibart license revenue. In June it cut its 2026 non-GAAP operating expense outlook to $420–440 million (from $450–470 million) after deciding to shut its internal discovery programs and close its Birmingham, Alabama research facility by the end of 2026.

First-half ORLADEYO revenue was $306.5 million, so hitting the $625–645 million range requires $318–338 million in the second half, i.e. modest sequential growth. Two things could help: the oral-pellet version of ORLADEYO for children began shipping the week of August 3 (47 prescriptions written year-to-date), and a switch to CareMed as sole specialty pharmacy from Q3. The switch is also a short-term risk if patient transfers cause shipment gaps.

The larger question sits further out. Navenibart's pivotal ALPHA-ORBIT trial finished enrolment in June, with results for both the every-three-month and every-six-month doses expected in Q3 2027. That readout will determine whether the Astria acquisition, and the debt taken on to pay for it, pays off. BCX17725, a drug for the skin disease Netherton syndrome, is expected to report Phase 1 patient data by the end of 2026.

Source: BioCryst Q2 2026 earnings release (Exhibit 99.1 to Form 8-K, filed August 5, 2026) and Form 10-Q for the quarter ended June 30, 2026.